N/A
N=300
Use of Remote Monitoring for COVID-19 Patient
COVID
Bottom Line
View on ClinicalTrials.gov: NCT04425720 ↗Enrolled (actual)
300
Serious AEs
1.1%
Results posted
Nov 2021
Primary outcome: Primary: Number of Monitored Versus Non-Monitored In-patient Admission — 8; 9 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- LifeSignals Biosensor 1AX* (Device); Standard of Care (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Montefiore Medical Center
- Primary completion
- Feb 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Monitored Versus Non-Monitored In-patient Admission |
8; 9 | — |
| PRIMARY How Many Subjects Needed to Visit the Emergency Department |
14; 12 | — |
| PRIMARY Length of Stay |
7; 7 | — |
| PRIMARY How Many Completed the Patient Satisfaction Survey |
84 | — |
| PRIMARY How Many Subjects End up Requiring Mechanical Ventilation and ECMO |
— | — |
| PRIMARY Serious Adverse Events |
2; 1 | — |
Summary
The central hypothesis motivating this study is that remote patient monitoring (RPM) of infectious disease patients can efficiently facilitate self-isolation. Additionally, RPM can assist in more rapid identification of patients at risk, facilitate detection of patient deterioration, and enable early interventions, all of which play a vital role in resource utilization and outcomes.
Eligibility Criteria
Inclusion Criteria
- Covid-19 positive patient
- Does not require in-patient admission
Exclusion Criteria
- Allergic to sensor patch
- Has implanted pacemaker
- Has excessive sweating
Data sourced from ClinicalTrials.gov (NCT04425720). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.